Ireland· IE-PA-EU/1/99/114/002
Zeffix 100 mg Film-coated tablet
A lamivudine product containing lamivudine, registered in Ireland by GlaxoSmithKline Trading Services Limited. The same ATC class is registered in 17 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Lamivudine is registered in 17 of 19 countries.
Countries holding a registration under ATC J05AF05 (lamivudine), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 10 of them publish a price we can compare per daily dose
Lamivudine · ATC J05AF05
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of lamivudine costs, country by country.
Normalised to the WHO defined daily dose (0.3 g), the median price runs from $2.42 in France to $7.71 in Switzerland — a ×3.2 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Lamivudine · price per daily dose (0.3 g)
USD · FX 28 Sept 2026
- CH Switzerland$7.71
- IT Italy$6.75
- FR France$2.42
The record
At a glance
HPRA (Ireland)- Active substance
- Lamivudine
- Manufacturer
- GlaxoSmithKline Trading Services Limited
- Country
- Ireland (IE)
- ATC code
- J05AF05
- ATC class
- Lamivudine
- Defined daily dose
- 0.3 g, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/99/114/002
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
207 interactions on record for lamivudine.
Graded by severity as the source publishes them — 6 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lamivudine · interactions on record
207 records
- 6 severe
- 36 moderate
- 165 info
Most severe, free to view
- BexaroteneL01XF03severe
- BexarotenL01XX25severe
- LeflunomidL04AA13severe
- TeriflunomidL04AA31severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Lamivudine in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaLAMIVUDIN TEVATeva B.V., Haarlem
- United StateslamivudineCamber Pharmaceuticals, Inc.
- ItalyLAMIVUDINA AUROBINDO ITALIAAUROBINDO PHARMA ITALIA S.R.L.
- SpainLAMIVUDINA ACCORD 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGAccord Healthcare S.L.U.
- NetherlandsLamivudine Accord 100 mg, filmomhulde tablettenAccord Healthcare B.V.
- BelgiumLamivudin Sandoz 100 mgSandoz
- PolandLamivudine AurovitasAurovitas Pharma Polska Sp. z o.o.
- FranceLAMIVUDINE ARROW 100 mg, comprimé pelliculéARROW GENERIQUES
Authorised across Europe · EMA
The same active substance is authorised in 13 EEA countries. Names it is sold under:
- Austria · Lamivudin Sandoz
- Cyprus · Lamivudine Normon
- Germany · Lamivudin Aurobindo, Lamivudin Mylan
- Spain · Lamivudina Accord, Lamivudina Aurovitas
- France · Lamivudine Arrow, Lamivudine Sandoz
- United Kingdom (Northern Ireland) · Lamivudine Amarox, Lamivudine Generics
- Iceland · Epivir, Lamivudine Teva
- Italy · Lamivudina Aurobindo, Lamivudina Aurobindo Italia
- Liechtenstein · Epivir, Lamivudine Teva
- Netherlands · Lamivudine Accord, Lamivudine Aurobindo
- Norway · Epivir, Lamivudine Teva
- Poland · Lamivudine Aurovitas
- Portugal · Lamivudina Aurobindo, Lamivudina Farmoz
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/df380d55-c2f6-4581-b31f-6738066d66b0 GET /v1/drugs/df380d55-c2f6-4581-b31f-6738066d66b0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"J05AF",
"J05AF05"
],
"strength": null,
"pa_number": "EU/1/99/114/002",
"substances": [
"Lamivudine"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "29/07/1999",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about lamivudine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.